Insider Transactions in Q4 2021 at Editas Medicine, Inc. (EDIT)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2021
|
James C Mullen CEO |
BUY
Grant, award, or other acquisition
|
Direct |
36,477
+27.92%
|
-
|
|
Dec 22
2021
|
Michelle Robertson EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,471
+11.87%
|
-
|
|
Dec 22
2021
|
Mark S Shearman EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,084
+17.86%
|
-
|
|
Dec 22
2021
|
Lisa Anne Michaels EVP/Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,243
+15.76%
|
-
|
|
Dec 22
2021
|
Bruce Eaton EVP, CBO AND CTO |
BUY
Grant, award, or other acquisition
|
Direct |
3,472
+9.93%
|
-
|
|
Nov 12
2021
|
Lisa Anne Michaels EVP/Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,568
-7.84%
|
$59,584
$38.33 P/Share
|
|
Nov 09
2021
|
Bruce Eaton EVP, CBO AND CTO |
SELL
Open market or private sale
|
Direct |
287
-1.01%
|
$11,480
$40.61 P/Share
|
|
Oct 18
2021
|
James C Mullen CEO |
SELL
Open market or private sale
|
Direct |
13,805
-19.31%
|
$524,590
$38.03 P/Share
|